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Most cancers are sporadic, but 5-10% of all cancer is hereditary, or caused by a 
heritable genetic mutation. A patient’s medical history, family history, genetic test 
results, intact organs (e.g., ovaries) at an increased risk for developing cancer, and the 
availability and accessibility of interventions are used to make recommendations for 
cancer-risk management. In addition to basic medical care, transgender patients have 
healthcare needs that differ from those of cisgender patients such as expert care related to 
using hormones or having gender-affirming surgery, as well as unique mental health 
concerns. Transgender individuals may also experience a greater number of barriers to 
accessing care than cisgender individuals.  
The purpose of this study was to explore the motivations and needs of transgender 
individuals who may seek cancer genetic counseling. We aimed to determine where 
current practices could be improved to increase comfortability and inclusivity of 
transgender patients. Eighty-seven transgender individuals participated in an online 
questionnaire that asked about their personal perspectives on comfort and preferences 
regarding current genetic counseling practices.  
Most participants reported that they would feel comfortable sharing their pronouns, 
hormone therapies, and surgical history on an intake form before their genetic counseling 
appointment. The results suggested that comfort levels between the different current 
practices regarding pedigree nomenclature had no statistical differences, although most 
participants would not be comfortable being represented as their sex assigned at birth on 
iv 
a pedigree. When assessing motivations, evidence demonstrated that most participants 
would want to discuss how hormone and surgical therapies could impact personal cancer 
risk. These findings reinforce recommendations from existing literature regarding the 
adaptation and evolution of current practices to meet the needs of transgender patients 
while highlighting the need for standardized training in order to provide comprehensive, 
inclusive care for all patients, regardless of gender identity. 
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1.1 Introduction to Hereditary Cancer 
Cancer is one of the most prevalent diseases worldwide. The National Cancer 
Institute (NCI) is the principal agency for conducting and supporting cancer research, 
prevention, diagnosis, and treatment in the United States. The NCI has been documenting 
cancer incidence data in the Surveillance, Epidemiology, and End Results (SEER) 
Program since 1973 and makes the data publicly accessible online. According to SEER, 
there were 1,806,590 new cases of cancer in 2020. While most cancers are sporadic, 
approximately 5-10% of all cancer is hereditary – it occurs in a person with a heritable 
genetic mutation in a cancer predisposition gene (Dalton et al., 2014). When an 
individual has a genetic predisposition to cancer, they are at an increased risk for 
developing certain types of cancer depending on which gene has a mutation. Hereditary 
cancers tend to occur at younger ages than sporadic cancers and individuals with a 
hereditary cancer syndrome can have multiple cancers in their lifetime.  
Based on these risks, the National Comprehensive Cancer Network (NCCN) has 
published guidelines for genetic testing for hereditary cancer syndromes and cancer risk 
management in individuals who have hereditary cancer predisposition syndromes. These 
recommendations for cancer screenings and preventative therapies aim to reduce the 
probability that cancer will occur or reoccur in these individuals. For example, the NCCN 
Guidelines for Genetic/Familial High-Risk Assessment for Breast, Ovarian, and 
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Pancreatic cancers include criteria for factors in an individual’s personal and family 
medical history make them an appropriate candidate for genetic counseling and genetic 
testing. Some of these factors include being diagnosed with breast cancer under 46-years-
old, metastatic prostate cancer at any age, or having a blood relative with a known 
mutation in a cancer susceptibility gene (NCCN 2020). 
If someone is found to be at an increased risk for developing cancer based on their 
family history or their genetic testing results, the NCCN recommends earlier and 
increased cancer surveillance. Some of these recommendations include starting breast 
magnetic-resonance imaging (MRI), mammograms, colonoscopies, endoscopies, and 
other screenings at younger ages or undergoing these cancer screenings more frequently 
in order to identify cancers earlier and optimize any necessary treatment.  
1.2 Genetic Counseling and Testing for Cancer Predispositions 
Physicians use the NCCN guidelines as well as other recommendations from 
professional societies such as the American Cancer Society, American College of 
Obstetricians and Gynecologists, and the American College of Medical Genetics and 
Genomics to determine which of their patients need to be referred to a genetic counselor, 
based on that individual’s personal and family history.  
Genetic counselors are healthcare professionals with training in both medical genetics 
and psychosocial counseling. A cancer genetic counselor specializes in evaluating 
patients for hereditary cancer syndromes. In a typical cancer genetic counseling session, 
the genetic counselor elicits a patient’s personal and family medical history and conducts 
a risk assessment to determine the likelihood that a patient’s cancer or the cancer in their 
family may be caused by a genetic predisposition syndrome. The genetic counselor then 
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communicates that risk assessment to the patient, facilitates decision making regarding 
options for genetic testing, educates the patient on cancer surveillance and prevention, 
and arranges genetic testing when appropriate (Schneider, 2011). During a genetic 
counseling session, the counselor also explores psychosocial issues regarding motivations 
for testing, feelings about the risk information, and overall emotional state of the patient. 
When eliciting a patient’s family history, the genetic counselor will document the 
information as a pedigree, or a diagram of the family tree. Once the pedigree is drawn, 
the genetic counselor looks for patterns that are consistent with those seen in hereditary 
cancer syndromes and presents this information to the patient as a probability that they 
could have a hereditary cancer syndrome. The goal of providing this information is to aid 
in the patient’s decision making about genetic testing and future medical management. If 
a patient decides to pursue genetic testing, the genetic counselor helps them with 
decisions regarding appropriate testing and follow-up (Glessner et al., 2012).  
The National Society of Genetic Counselors (NSGC) has established Practice 
Guidelines for Human Pedigree Nomenclature. The purpose of these guidelines is to 
create a standardized way to accurately and appropriately represent individuals, their 
relationships, and their medical status for risk assessment and future reference for other 
medical providers (Bennett et al., 2008). Traditionally, based on the binarization of 
gender in most Western cultures, females and males have been represented by circles and 
squares, respectively. If an individual’s gender is unknown, they may be represented by a 
diamond (Bennett et al., 2008; Sutherland et al., 2020).  
The most recent update to these guidelines was in 2008, which recommended a 
standardized way of representing transgender individuals. However, periodic revision of 
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these guidelines is imperative to ensure inclusivity of all patients (Sheehan et al., 2020). 
The NCCN and NSGC guidelines on how to represent transgender individuals on a 
pedigree differ and there is currently no universally accepted and standardized way to 
represent gender identity and sex assigned at birth. The lack of consensus creates 
confusion between medical professionals and does not validate the gender identity of 
transgender patients. There have been suggestions to create a unique symbol for 
transgender and nonbinary patients within the field of genetic counseling, which 
underlines the need for standardization and reform of the current practice guidelines 
(Sheehan et al., 2020; Tuite et al., 2020).  
1.3 Overview of Transgender Healthcare  
A person’s sexuality and gender are made up of many features including gender 
identity, gender expression, sex assigned at birth, and sexual orientation. Several 
transgender education and advocacy organizations have published infographics to explain 
these aspects of the gender and sexuality spectrums. To describe gender identity, three 
independent spectrums are used to measure the degree to which someone identifies with 
the female gender, male gender, or other genders (Coleman et al., 2012). Gender 
expression is the degree to which someone outwardly expresses themselves in a feminine, 
androgenous, or masculine way. In the United States, children are typically assigned 
male, female, or intersex at birth before their gender identity is developed, which is 
known as “sex assigned at birth” (Puechl et al., 2019).  
According to the Centers for Disease Control and Prevention’s (CDC) 2018 
Behavioral Risk Factor Surveillance System (BRFSS), over 1.4 million Americans 
identify as transgender and/or nonbinary. The term “transgender” is used to describe 
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people whose gender identity does not align with their sex assigned at birth. “Cisgender” 
is a term used to describe individuals whose gender identity does alighn with their sex 
assigned at birth. Someone who is transgender may identify with the female gender, male 
gender, another gender, no gender, or a combination of genders. Someone who does not 
identify with the female or male genders may describe their gender as “nonbinary” 
(Rafferty, 2018). When a person’s gender does not align with their sex assigned at birth, 
they may choose to express their gender through social changes, hormonal therapies, 
and/or surgical transitions.  
The World Professional Association for Transgender Health (WPATH) published 
Standards of Care for the Health of Transsexual, Transgender, and Gender-
Nonconforming People. These guidelines describe therapies available to aid in the 
transition from sex assigned at birth to true gender, including hormonal and surgical 
options. Hormone therapy is the use of hormones to induce more feminine or masculine 
secondary sex characteristics. Changes that occur in individuals who are prescribed 
gender-affirming hormones typically occur over the course of two to five years. There are 
some possible risks to taking these hormones, including a potential increase in cancer 
risk, although much of the data is minimal and sometimes conflicting (Sutherland et al., 
2020). 
Gender-affirming surgeries may involve altering an individual’s breast tissue, ovaries, 
and genitalia. Breast and chest reconstruction may be referred to as “top surgery” and 
typically involves either a breast augmentation mammoplasty or a subcutaneous 
mastectomy with chest contouring (Coleman et al., 2012). Subcutaneous, or nipple-
sparing mastectomies, are not typically prophylactic bilateral total mastectomies, which is 
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the recommended surgical prevention for some high-risk hereditary breast cancer 
syndromes (Guillem et al., 2020). Additional surgical transitions may include “bottom 
surgery,” or surgery involving reproductive and/or genital organ reconstruction or 
removal (Coleman et al., 2012). Surgery to remove reproductive organs such as the uterus 
(hysterectomy) or ovaries and fallopian tubes (salpingo-oophorectomy) may be available 
for gender-affirming surgery. Currently, a risk-reducing bilateral salpingo-oophorectomy 
(BSO) is the most effective means of decreasing ovarian cancer risk in individuals with 
high-risk hereditary cancer syndromes Guillem et al., 2020). This surgery is performed 
differently and removes larger amount of tissue than a BSO for non-risk-reducing 
reasons, such as surgical transition. Surgery to remove the prostate (prostatectomy) is not 
typically offered as part of a gender-affirming surgery and is also not typically 
recommended as a risk-reduction option in most cases of high-risk hereditary cancer 
syndromes. Possible risks associated with gender-affirming surgeries are those of typical 
surgery-related complications (Coleman et al., 2012). Because there is limited data on the 
effects that these therapies have on cancer risk, transgender and gender nonconforming 
patients who present for cancer risk assessment require a more personalized approach to 
discussing gender-affirming interventions and management options (Sutherland et al., 
2020).  
1.4 Health Disparities in Cancer Care  
There are significant barriers that limit access to gender-affirming therapies and 
general healthcare services among gender-diverse populations (Berro, et al., 2019; Harb 
et al., 2019; Haviland et al., 2020; Sacca et al., 2019; Sutherland et al., 2020; Zayhowski 
et al., 2019). These barriers include lack of competent care, inhibited access to health 
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insurance, and limited availability of inclusive and comfortable healthcare environments 
(Edmiston et al., 2016; Harb et al., 2019; Haviland et al., 2020). It has been shown that 
healthcare providers with professional education and formal training regarding care for 
lesbian, gay, bisexual, transgender, and questioning (LGBTQ) individuals demonstrate an 
increase in knowledge and competency when serving these patient populations 
(Hardacker et al., 2014; Johnson et al., 2016). Patients who are currently employed, have 
higher annual incomes, have completed higher levels of education, and have health 
insurance are more likely to adhere to cancer screening and prevention recommendations 
than those who do not (Johnson et al., 2016). Adults who are of ethnic minorities are 
more likely than white adults to identify as a gender minority, which can compound these 
barriers and further limit and prevent access to medical care, ultimately leading to worse 
health outcomes (Center for Disease Control and Prevention 2018). 
Without accurate, standardized documentation of gender diversity in most medical 
record systems, cancer rates among transgender people are poorly understood. The SEER 
database does not collect gender identity information, therefore there is no way to 
determine cancer rates among transgender patients at a population level. Individuals who 
are at high risk for developing cancer, including individuals with hereditary cancer 
syndromes, have specific screening recommendations that they should follow based on 
the specific body tissues they have. Based on the information that is available, 
transgender individuals have been reported to have extremely low uptake on all cancer 
screenings. Transgender and gender-nonconforming individuals have lower proportions 
of routine colorectal cancer screening compared to cisgender individuals (Tabaac et al., 
2018). Transgender individuals are also less likely to adhere to breast cancer screening 
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recommendations (Bazzi et al., 2015). Receiving less cancer surveillance contributes to 
increased time to cancer diagnosis which leads to increased rates of morbidity and 
mortality among transgender patients (Sutherland et al., 2020). 
High-risk individuals who have at-risk body tissues, regardless of gender, should 
follow the NCCN Guidelines for hereditary cancer management. However, there are no 
evidence-based cancer screening guidelines specifically for transgender patients. Breast 
tissue, one or both ovaries, a uterus, and/or a prostate are of specific importance to 
transgender individuals, because these body systems are at an increased risk for tumor 
development with many genetic predisposition syndromes. Additionally, some 
individuals may have elected to have that tissue removed before the genetic counseling 
session or may want to learn more about their options for removal of certain at-risk 
tissues during the session. Transgender men may elect to have chest surgery to create a 
more masculine appearance, however, this does not eliminate their breast cancer risk, as 
there is some residual tissue left over (Alaofi et al., 2018; Griepsma et al., 2014).  
Some research has been published regarding care for sexual minorities, however, 
gender diverse individuals are vastly underrepresented in literature regarding cancer 
screening and genetic counseling (Haviland et al., 2020). The transgender population is 
generally absent from the little data that does exist on LGBTQ individuals 
(VandenLangenberg et al., 2011). In the studies that include lesbian, gay, and bisexual 
patients, genetic counselors report overall that they do not adjust their counseling 
approaches (Glessner et al., 2012). When it comes to pedigree drawing, genetic 
counselors have standard nomenclature dictated by NSGC and the NCCN on how to 
represent different individuals, relationships, and disease status, which, in a cancer 
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setting, would be cancer diagnoses. The information that exists on how to represent 
transgender and gender-nonconforming individuals is limited and inconsistent (Berro et 
al., 2019; Sheehan et al., 2020). The inconsistencies in recommendations from national 
organizations make it difficult to properly represent these individuals in a standardized, 
informative, and respectful way. 
1.5 Rationale 
Little research has been conducted to assess the feelings and experiences of 
transgender patients regarding current genetic counseling practices. Most of the 
information that is available comes from case studies or from the perspective of genetic 
counselors rather than of transgender community members. Additionally, each of these 
studies calls for a greater exploration of the views of transgender patients themselves. To 
our knowledge, no research has been conducted to assess the perspectives of transgender 
individuals who have not had cancer genetic counseling specifically regarding anticipated 
needs and perceived barriers to accessing genetics care.  
The identification of a pathogenic genetic variant that increases someone’s risk to 
develop cancer could impact a transgender patient’s decisions about hormonal or surgical 
medical interventions. There is limited information available on the unique needs of 
transgender individuals in a cancer genetic counseling session. This population may be a 
significant portion of the patients seen in clinics, and there are currently no standardized 
guidelines or recommendations for how to care for transgender patients in a cancer 
genetics setting (Barnes et al., 2019; Rafferty 2018; Sheehan et al., 2020). To meet the 
needs of this patient population, patient perspectives must be assessed. This study aimed 
to determine what aspects of current genetic counseling practice and training need to be 
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adapted to benefit this patient population. We anticipated that the results of the study 
would aid in the optimization and standardization of cancer genetic counseling strategies 
for transgender patients. 
1.6 Purpose 
This project was conducted to assess the anticipated needs of transgender adults 
during a cancer genetic counseling session. The primary goal of this study was to 
determine the informational and psychosocial needs of transgender patients who may 
present for cancer genetic counseling. This study also aimed to identify motivations and 
barriers to seeking genetic counseling. The information collected was be compared to 
previously reported perspectives of cancer genetic counselors on their experiences with 
counseling transgender individuals about hereditary cancer risk. Finally, through this 
study, we hoped to recognize themes to assist in standardization of practice and 
optimization of care of gender minority patients. 
This study aimed to provide genetic counseling research surrounding transgender 
healthcare, which is currently sparse and limited. While there is literature that assesses 
the needs of patients who identify as a sexual minority, research regarding how genetic 
counselors can meet the needs of transgender patients specifically is minimal. In the 
NSGC 2020 Professional Status Survey–an internally administered survey that assesses 
metrics of current genetic counselors such as demographics, salary, and workforce 
satisfaction–only two genetic counselors indicated non-binary or third gender identities. 
The literature that does exist regarding transgender patients is predominantly from the 
perspective of genetic counselors, most of whom do not identify as transgender or non-
binary, leaving the transgender voice largely absent. The informational, psychosocial, and 
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medical management needs of transgender individuals is likely different from those of 
cisgender patients. Therefore, it is important to explore the perspectives of these patients 
to gain information about how best to care for them. Without intentional surveying of 
gender minority patients, genetic counselors will remain underprepared to care for a 
portion of the patient population. In existing literature, genetic counselors indicated a 
desire for more data and education regarding counseling transgender patients (Zayhowski 
et al., 2019). 
Identifying the needs of transgender patients adds to the cultural competence that 
genetic counselors must have to effectively serve patients, making the information gained 
from exploring these perspectives valuable to the profession. Cultural competency is a 
core value of the genetic counseling field, as it encourages genetic counselors to 
understand each patient’s family, community, and culture to better empathize with 
patients’ thoughts, feelings, and values. Understanding the motivations and needs of 
transgender people who may present for cancer genetic counseling is the only way to 
competently counsel these patients. It is the duty of genetic counselors to be 
knowledgeable and sensitive to diverse languages, cultures, beliefs, and backgrounds to 
provide optimal care (Warren & Wilson 2013). The information gained from surveying 
patients directly will prepare current and future genetic counselors for interactions with 
all patients, including transgender and gender nonconforming patients. 
We predicted that transgender individuals have needs within the cancer genetic 
counseling session that are similar to cisgender patients as well as needs that are unique 
to their gender identity. We expected that transgender individuals would find value in 
discussing how future healthcare plans regarding gender-affirming therapies could be 
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impacted by a hereditary predisposition to cancer. Results from this study may also 
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Most cancers are sporadic, but 5-10% of all cancer is hereditary, or caused by a 
heritable genetic mutation. A patient’s medical history, family history, genetic test 
results, intact organs (e.g., ovaries) at an increased risk for developing cancer, and the 
availability and accessibility of interventions are used to make recommendations for 
cancer-risk management. Transgender patients have healthcare needs that differ from 
those of cisgender patients such as expert care related to using hormones or having 
gender-affirming surgery, as well as unique mental health concerns. Transgender 
individuals may also experience a greater number of barriers to accessing care than 
cisgender individuals. 
The purpose of this study was to explore the motivations and needs of transgender 
individuals who may seek cancer genetic counseling. We aimed to determine where 
current practices could be improved to increase comfortability and inclusivity of 
transgender patients. Eighty-seven transgender individuals participated in an online 
questionnaire that asked about their personal perspectives on comfort and preferences 
regarding current genetic counseling practices.  
Most participants reported that they would feel comfortable sharing their pronouns, 
hormone therapies, and surgical history on an intake form before their genetic counseling 
appointment. The results suggested that comfort levels between the different current 
practices regarding pedigree nomenclature had no statistical differences, although most 
participants would not be comfortable being represented as their sex assigned at birth on 
a pedigree. When assessing motivations, survey responses demonstrated that most 
participants would want to discuss how hormone and surgical therapies impact personal 
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cancer risk. These findings reinforce recommendations from existing literature regarding 
the adaptation and evolution of current practices to meet the needs of transgender patients 
while highlighting the need for standardized training in order to provide comprehensive, 
inclusive care for all patients, regardless of gender identity. 
2.2 Introduction 
A person’s sexuality and gender are made up of many features including gender 
identity, gender expression, sex assigned at birth, and sexual orientation (see Table 2.1 
for a glossary of terms used in this paper). In the United States, where children are 
typically assigned a sex at birth before they develop their gender identity, over one 
million Americans identify as transgender and/or nonbinary (Puechl et al., 2019, Rafferty 
2018). When a person’s gender does not align with their sex assigned at birth, they may 
choose to express their gender through social changes, hormonal therapies, and/or 
surgical transitions.  
 
Table 2.1 Glossary of Terms  
Term Definition 
Cis/Cisgender Used to describe a person whose gender identity and gender 
expression align with sex assigned at birth and culturally 
defined gender roles. 
Gender Refers to the attitudes, feelings, and behaviors that a given 
culture associates with a person’s assigned sex. 
Gender Dysphoria Discomfort of distress related to incongruence between a 
person's gender identity, sex assigned at birth, and/or primary 
sex characteristics. 
Gender Expression The presentation of an individual, including physical 
appearance, clothing choice and accessories, and behaviors 
that express aspects of gender identity or role. 
Gender Identity A person's inherent sense of self as it relates to gender. 
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Nonbinary Used to describe a person whose gender identity does not 
align with a binary understanding of gender such as a person 
who may identify as a combination of genders, who does not 
define themselves as gendered, or who embodies a third 
gender.  
 
Nonbinary can include agender, bigender, demigender, 
genderfluid, gender-nonconforming, gender-neutral, 
genderqueer, pangender, or traditional third-genders such as 
Two-Spirits and Muxes. 
Gender Role The culturally defined pattern of behavior, personality traits, 
and attitudes that define masculinity and femininity. 
Intersex Used to describe a person who was born with variation in their 
sex traits and reproductive anatomy such as gonads, internal 
reproductive organs,  external genitalia, and hormone 
production.  
 
Intersex is not used to describe individuals based on sex 
chromosome configuration alone. 
LGBTQ An acronym for "Lesbian, Gay, Bisexual, Transgender, Queer 
or Questioning, Intersex, and Allies." 
"Top Surgery" Surgical transition through breast augmentation mammoplasty 
or subcutaneous mastectomy with chest contouring. 
"Bottom Surgery" Surgical transition through reproductive and/or genital organ 
reconstruction or removal. 
Risk-Reducing 
Mastectomy 
A prophylactic surgery that involves the removal of breast 
tissue. A total mastectomy, complete removal of both breasts 
including nipples, provides greater risk reduction than a 
subcutaneous, nipple-sparing, mastectomy. 
Sex/Sex Assigned at 
Birth 
Refers to physical and biological traits prior-to or following 
birth such as sex chromosomes, gonads, internal reproductive 
organs, and external genitalia. Typically described as male 
(AMAB), female (AFAB), or intersex (AIAB or UAAB). 
Transgender Used to describe the full range of people whose gender 
identity does not conform to the gender role that is culturally 
associated with their sex assigned at birth. 
Transitioning The psychological, social, hormonal, surgical and legal 
processes by which some people strive to more closely align 
their gender identity and gender expression. 
Two-Spirit A pan-Indian term used to describe a Native American or 
Alaskan Native who identifies with third gender or an 
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alternative gender status. Many tribes and cultures have 
additional specific terms for their nonbinary genders. 
 
The National Cancer Institute (NCI) has been publicly documenting cancer incidence 
data online in the Surveillance, Epidemiology, and End Results (SEER) Program since 
1973. According to SEER, there were 1,806,590 new cases of cancer in 2020. While 
most cancers are sporadic, approximately 5-10% of all cancer is hereditary, or caused by 
a heritable genetic mutation in a cancer predisposition gene (Dalton et al., 2014). When 
an individual has a genetic predisposition to cancer, they are at an increased risk for 
developing certain types of cancer, depending on which gene has a mutation. Hereditary 
cancers tend to occur at younger ages than sporadic cancers and individuals with a 
hereditary cancer syndrome can have multiple cancers in their lifetime.  
Based on these risks, the National Comprehensive Cancer Network (NCCN) has 
published guidelines for genetic testing for hereditary cancer syndromes and cancer risk 
management in individuals who have genetic cancer predispositions. These 
recommendations for cancer screenings and preventative therapies aim to reduce the 
probability that cancer will occur or reoccur in these individuals. If someone is at an 
increased risk for developing cancer, recommendations may include earlier and increased 
cancer surveillance or prophylactic surgical prevention.  
Genetic counselors are healthcare professionals with training in both medical genetics 
and psychosocial counseling. A cancer genetic counselor specializes in evaluating 
patients for hereditary cancer syndromes. In a typical cancer genetic counseling session, 
the genetic counselor elicits a patient’s personal and family medical history and conducts 
a risk assessment to determine the likelihood that a patient’s cancer or the cancer in their 
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family may be caused by a genetic predisposition syndrome. The genetic counselor then 
communicates that risk assessment to the patient, facilitates decision making regarding 
options for genetic testing, educates the patient on cancer surveillance and prevention, 
and arranges genetic testing when appropriate (Schneider, 2011). During a genetic 
counseling session, the counselor also explores psychosocial issues regarding motivations 
for testing, feelings about the risk information, and overall emotional state of the patient. 
When eliciting a patient’s family history, the genetic counselor will document the 
information as a pedigree, or a diagram of the family tree. The National Society of 
Genetic Counselors (NSGC) has established Practice Guidelines for Human Pedigree 
Nomenclature, most recently revised in 2008. The NCCN has also published 
recommendations for pedigree nomenclature that differ slightly from the NSGC Practice 
Guidelines. The purpose of these guidelines is to create a universally accepted way to 
accurately and appropriately represent individuals, their relationships, and their medical 
status for risk assessment and future reference for other medical providers (Bennett et al., 
2008). Traditionally, based on the binarization of gender in most Western cultures, 
females and males have been represented by circles and squares, respectively. If an 
individual’s gender is unknown, they may be represented by a diamond according to the 
NSGC guidelines or a combination of a square and circle per the NCCN (Bennett et al., 
2008; Sutherland et al., 2020). The lack of consensus creates confusion between medical 
professionals and does not validate the gender identity of transgender patients. There 
have been suggestions to create a unique symbol for transgender and nonbinary patients 
within the field of genetic counseling, which underlines the need for standardization and 
reform of the current practice guidelines (Sheehan et al., 2020; Tuite et al., 2020).  
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The World Professional Association for Transgender Health (WPATH) published 
Standards of Care for the Health of Transsexual, Transgender, and Gender-
Nonconforming People. These Standards of Care guidelines describe therapies available 
to aid in the transition from sex assigned at birth to true gender, including hormonal and 
surgical options. There are some possible risks to taking these hormones, including a 
potential increase in cancer risk, although much of the data is minimal and sometimes 
conflicting (Sutherland et al., 2020). 
Breast and chest reconstruction may be referred to as “top surgery” and typically 
involves either a breast augmentation mammoplasty or a subcutaneous mastectomy with 
chest contouring (Coleman et al., 2012). Subcutaneous, or nipple-sparing mastectomies, 
are not typically prophylactic bilateral total mastectomies, which is the recommended 
surgical prevention for some high-risk hereditary breast cancer syndromes (Alaofi et al., 
2018; Griepsma et al., 2014; Guillem et al., 2020). Additional surgical transitions may 
include “bottom surgery,” or surgery involving reproductive and/or genital organ 
reconstruction or removal (Coleman et al., 2012). Surgery to remove reproductive organs 
such as the uterus (hysterectomy) or ovaries and fallopian tubes (salpingo-oophorectomy) 
may be available for gender-affirming surgery. Currently, a risk-reducing salpingo-
oophorectomy (RRSO) is the most effective means of decreasing ovarian cancer risk in 
individuals with high-risk hereditary cancer syndromes (Guile et al., 2020). Surgery to 
remove the prostate (prostatectomy) is not frequently offered as part of a gender-
affirming surgery and is also not typically recommended in most cases of high-risk 
hereditary cancer syndromes. Because there is limited data on the effects that these 
therapies have on cancer risk, transgender and gender nonconforming patients who 
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present for cancer risk assessment require a more personalized approach to discussing 
gender-affirming interventions and management options (Sutherland et al., 2020).  
There are significant barriers that limit access to gender-affirming therapies and 
general healthcare services among gender-diverse populations (Berro, et al., 2019; Harb 
et al., 2019; Haviland et al., 2020; Sacca et al., 2019; Sutherland et al., 2020; Zayhowski 
et al., 2019). These barriers include lack of competent care, inhibited access to health 
insurance, and limited availability of inclusive and comfortable healthcare environments 
(Edmiston et al., 2016; Harb et al., 2019; Haviland et al., 2020). It has been shown that 
healthcare providers with professional education and formal training regarding care for 
lesbian, gay, bisexual, transgender, and questioning (LGBTQ) individuals demonstrate an 
increase in knowledge and competency when serving these patient populations 
(Hardacker et al., 2014; Johnson et al., 2016). Patients who are currently employed, have 
higher annual incomes, have completed higher levels of education, and have health 
insurance are more likely to adhere to cancer screening and prevention recommendations 
than those who do not (Johnson et al., 2016). Adults who are of ethnic minorities are 
more likely than white adults to identify as a gender minority, which can compound these 
barriers and further limit and prevent access to medical care, ultimately leading to worse 
health outcomes (Center for Disease Control and Prevention 2018). 
Without the ability to document gender diversity in most medical record systems, 
cancer rates among transgender people are poorly understood. The SEER database does 
not collect gender identity information, therefore there is no way to determine cancer 
rates among transgender patients at a population level. Individuals who are at high risk 
for developing cancer, including individuals with hereditary cancer syndromes, have 
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specific screening recommendations that they should follow based on what body tissues 
they have. Breast tissue, one or both ovaries, a uterus, and/or a prostate are of specific 
importance to transgender individuals, because these body systems are at an increased 
risk for tumor development with many genetic predisposition syndromes. Based on the 
information that is available, transgender individuals have been reported to have 
extremely low uptake on all cancer screenings. Transgender and gender-nonconforming 
individuals have lower proportions of routine colorectal cancer screening and are less 
likely to adhere to breast cancer screening recommendations compared to cisgender 
patients (Bazzi et al., 2015; Tabaac et al., 2018). Receiving less cancer surveillance 
contributes to increased time to cancer diagnosis which leads to increased rates of 
morbidity and mortality among transgender patients (Sutherland et al., 2020). 
Little research has been conducted to assess the feelings and experiences of 
transgender patients regarding current genetic counseling practices. In the NSGC 2020 
Professional Status Survey–an internally administered survey that assesses metrics of 
current genetic counselors such as demographics, salary, and workforce satisfaction–only 
two genetic counselors indicated non-binary or third gender identities. The literature that 
does exist regarding transgender patients is predominantly from the perspective of 
genetic counselors, most of whom do not identify as transgender or non-binary, leaving 
the transgender voice largely absent. Additionally, each of these studies calls for a greater 
exploration of the views of transgender patients themselves. To our knowledge, no 
research has been conducted to assess the perspectives of transgender individuals who 
have not had cancer genetic counseling specifically regarding anticipated needs and 
perceived barriers to accessing genetics care.  
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This population may be a significant portion of the patients seen in clinics, and there 
are currently no standardized guidelines or recommendations for how to care for 
transgender patients in a cancer genetics setting (Barnes et al., 2019; Rafferty 2018; 
Sheehan et al., 2020). To meet the needs of this patient population, patient perspectives 
must be assessed. This study aims to determine what aspects of current genetic 
counseling practice and training need to be adapted in order to optimize cancer genetic 
counseling strategies for this patient population. The primary goal of this study was to 
determine the informational and psychosocial needs of adult transgender patients who 
may present for cancer genetic counseling while identifying motivations and barriers to 
seeking genetic counseling.  
This study aimed to provide genetic counseling research surrounding transgender 
healthcare, which is currently sparse and limited. While there is literature that assesses 
the needs of patients who identify as a sexual minority, research regarding how genetic 
counselors can meet the needs of transgender patients specifically is minimal 
(VandenLangenberg et al., 2011). In the studies that include lesbian, gay, and bisexual 
patients, genetic counselors report overall that they do not adjust their counseling 
approaches (Glessner et al., 2012). Without intentional surveying of gender minority 
patients, genetic counselors will remain underprepared to care for a portion of the patient 
population. In existing literature, genetic counselors indicated a desire for more data and 
education regarding counseling transgender patients (Zayhowski et al., 2019). 
Identifying the needs of transgender patients adds to the cultural competence that 
genetic counselors must have to effectively serve patients, making the information gained 
from exploring these perspectives valuable to the profession. Cultural competency is a 
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core value of the genetic counseling field, as it encourages genetic counselors to 
understand each patient’s family, community, and culture to better empathize with 
patients’ thoughts, feelings, and values. Understanding the motivations and needs of 
transgender people who may present for cancer genetic counseling is the only way to 
competently counsel these patients. It is the duty of genetic counselors to be 
knowledgeable and sensitive to diverse languages, cultures, beliefs, and backgrounds to 
provide optimal care (Warren & Wilson, 2013). The information gained from surveying 
patients directly will prepare current and future genetic counselors for interactions with 
all patients, including transgender and gender nonconforming patients. 
We predicted that transgender individuals have needs within the cancer genetic 
counseling session that are similar to cisgender patients, as well as needs that are unique 
to their gender identity. We expected that transgender individuals would find value in 
discussing how future healthcare plans regarding gender-affirming therapies could be 
impacted by a hereditary predisposition to cancer. Results from this study may also 
provide clarification on current practices regarding official pedigree standards.   
2.3 Materials and Methods 
2.3.1 Participants and Recruitment 
Participants included English-speaking individuals over the age of 18 who identify as 
transgender and/or nonbinary. Participants who were not over the age of 18 or did not 
identify as transgender were excluded from the study. Only English-speaking participants 
were included in this study due to limited resources for translation and interpretation 
from English to other languages. Survey exclusion criteria is detailed in Figure 2.1.  
24 
 
Figure 2.1 Methods by which participant eligibility was filtered to assess for eligibility. 
Participants included in the grey boxes were excluded from the study and not assessed in 
data analysis due to unmet inclusion criteria.  
 
Participants were recruited via an advertisement (Appendix A) on multiple Facebook  
pages for transgender individuals and hereditary cancer risk support groups. The 
advertisement included a description of the study and a link to the online questionnaire. 
Participation was voluntary and upon completion of the survey, respondents were given 
the opportunity to enter a raffle for one of five $25 Visa gift cards. Participants also had 
the opportunity to express interest in being contacted for a semi-structured phone 
interview.  
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2.3.2 Procedure  
The questionnaire was administered online through Qualtrics.com and included Likert 
scale, open-text entry, and multiple choice items. Data regarding gender identity, 
demographics, motivations for attending a cancer genetic counseling session, 
perspectives on current practices, personal medical history, and family history of cancer 
was collected. Participants were able to skip any question or leave the questionnaire at 
any time, so the completion rate varied. The semi-structured phone interviews were 
conducted by the principal investigator (JB) and included similar themes as the 
questionnaire.  
Responses were collected from July to October 2020. Of the 105 individuals who 
began the questionnaire, 87 participants submitted responses that were eligible for data 
analysis. Eligible responses were reviewed and of the 87 respondents, 61 participants 
provided answers to the entire questionnaire. Ten participants input their phone numbers 
into the online software and were contacted for a phone interview. Verbal consent for 
participation was requested at the beginning of each interview (Appendix C). On average, 
the interviews lasted 25 minutes (range 15-40 minutes). Interviews were recorded on the 
PI’s password protected computer and transcribed verbatim. 
2.3.3 Data Analysis  
Quantitative data were analyzed using descriptive statistics, reliability, and 
correlations as appropriate. Quantitative data were analyzed using Microsoft Excel 
software to perform Kruskal-Wallis (KW) test and Mann-Whitney U test for differences 
and associations between groups. Figures and tables were constructed using Microsoft 
PowerPoint software. The level of comfort and agreeability to several statements was 
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assessed using a Likert scale (1=strongly disagree; 5=strongly agree) and were 
represented with descriptive statistics (percentages, frequencies, and means). Due to lack 
of responses in the open-text entry fields, the qualitative data were descriptively 
summarized. Quotations from open-text entries and interviews were extracted and 
organized into categories when available.  
2.4 Results 
2.4.1 Demographic Information 
Of the 87 eligible respondents, 100% disclosed their gender identity with most 
participants identifying with more than one gender (Table 2.2). Demographic information 
such as age, race and ethnicity, education and employment, etc. was provided for 61 
participants (Table 2.3). The majority of participants were between 18- and 38-years-old, 
with most participants being 25- to 31-years-old. Almost all participants identified as 
White and Non-Hispanic. Participant education level ranged from some high school 
education to completed graduate degrees. Employed respondents with private health 
insurance were more likely to receive care from a center that specializes in transgender 
healthcare than participants who were unemployed or uninsured (Figure 2.2).  
 
Table 2.2 Participant Gender Identity Information  
Gender Total (N) Percent (%) 
Agender 5 8% 
Bigender 2 3% 
Demigender 2 3% 
Genderfluid 5 8% 
Genderqueer 9 15% 
Gender-nonconforming 8 13% 
Gender-neutral 3 5% 
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Gender-questioning 1 2% 
Gender-transitioning 4 7% 
Nonbinary 20 33% 
Transgender man 27 44% 
Transgender masculine 11 18% 
Transgender feminine 9 15% 
Transgender woman 17 28% 
Two-spirit 2 3% 
Prefer to self-describe 3 5% 
Prefer not to say 0 0% 
 
Table 2.3 Participant Demographic Information  
Participant characteristic Total (N) Percent (%) 
Age   
 18-24 years old 15 25% 
 25-31 years old 18 30% 
 32-38 years old 12 20% 
 39-45 years old 8 13% 
 46-52 years old 1 2% 
 53-59 years old 5 8% 
 60-66 years old 1 2% 
 67-73 years old 1 2% 
 74 years or older 0 0% 
 Prefer not to say 0 0% 
Race   
 African American or Black 0 0% 
 American Indian or 
Alaskan Native 
1 2% 
 Asian 2 3% 
 Caucasian or White 56 92% 
 Pacific Islander 0 0% 
 Prefer to self-describe 0 0% 
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 Prefer not to say 2 3% 
Ethnicity   
 Hispanic or Latinx 5 8% 
 Not Hispanic or Latinx 53 87% 
 Prefer not to say 3 5% 
Education level  0% 
 Some high school 3 5% 
 High school diploma or 
equivalent 
3 5% 
 Some college 22 36% 
 Technical, trade, or 
vocational training 
2 3% 
 College graduate 17 28% 
 Graduate degree 12 20% 
 Prefer not to say 2 3% 
Employment   
 Student 10 16% 
 Homemaker 1 2% 
 Military 0 0% 
 Employed 39 64% 
 Unemployed 5 8% 
 Retired 1 2% 
 Unable to work 3 5% 
 Prefer not to say 2 3% 
Income   
 $29,999 or less 16 26% 
 $30,000-39,999 11 18% 
 $40,000-49,999 8 13% 
 $50,000-59,999 4 7% 
 $60,000-69,999 7 11% 
 $70,000 or more 13 21% 
 Prefer not to say 2 3% 
Insurance   
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 No health insurance 9 15% 
 Private health insurance 40 66% 
 Public health insurance 10 16% 
 Prefer not to say 2 3% 
Receiving healthcare from a center that specializes in transgender healthcare 
 Yes 37 61% 
 No 22 36% 
 Prefer not to say 2 3% 
 
Figure 2.2 The impact of employment and health insurance status on receiving 
specialized healthcare at a center for transgender patients.  
   
2.4.2 Personal and Family History of Cancer 
Four participants had a previous diagnosis of cancer including breast cancer at 45-
years-old, cervical cancer at 25-years-old, bladder cancer at 29-years-old, and laryngeal 
cancer at 69-years-old. Although approximately half (42%) respondents reported limited 
knowledge of their family health history, 63 participants indicated a family history of at 
least one first- or second-degree relative who was diagnosed with cancer (Figure 2.3). 
The total number of cancer diagnoses reported exceeds 228 cases. On average, 
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participants had about 3 relatives who have been diagnosed with cancer. The most 
frequently reported types of cancer, when known, for these relatives was breast cancer 
and melanoma which were present in 43% and 41% of families, respectively.  
Figure 2.3 Number of participants that indicated how many of their first- and second-
degree relatives have been diagnosed with cancer.   
 
2.4.3 Current Practices  
The questionnaire asked participants to rate their level of comfort with different 
statements addressing the current practices of cancer genetic counselors using a Likert 
scale (1=strongly disagree; 4=strongly agree). Participants were asked generally about the 
importance of inclusivity within healthcare offices and appointments, preferred methods 
of disclosing information, and specifically about comfort communicating with family 
members (Table 2.4; Table 2.5). 
Most participants (89%) indicated that it is important to have visible signs in the 
waiting room or lobby regarding LGBTQ inclusivity. A large portion of participants 
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agreed that it is important for medical professionals use appropriate and inclusive 
language both on intake forms and during the appointment. Participants generally 
indicated that they would feel comfortable sharing cancer risk information with their 
relatives, both with and without assistance from a genetic counselor (Table 2.4; Figure 
2.4). Most participants (79%) who indicated they would not share cancer risk information 
with their families without the assistance of a genetic counselor said they would if they 
did have that assistance in the form of a family letter, phone call, or family appointment. 
Some participants indicated that the importance of each item would depend on the 
specific situation or circumstances and elaborated in the open-text entry field associated 
with that section of the survey. 
 














If I was at an 
increased risk to 
develop cancer due 
to a genetic cause, I 
would feel 
comfortable sharing 
this with my 
relatives without 
assistance from a 
genetic counselor. 
4 (6.4%) 10 (15.9%) 21 (33.3%) 17 (27%) 10 (15.9%) 
If I was at an 
increased risk to 
develop cancer due 
to a genetic cause, I 
would feel 
comfortable sharing 
this with my 
relatives with 
assistance from a 
0 (0%) 5 (8.1%) 32 (51.6%) 16 (25.8%) 7 (11.3%) 
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genetic counselor 
like a family letter, 
















I would prefer being asked 
directly about my pronouns over 
voluntarily sharing them. 
3 (4.8%) 2 (3.2%) 25 (40.3%) 29 (46.8%) 
I would feel comfortable sharing 
my pronouns on an intake form 
before my genetic counseling 
appointment. 
0 (0%) 1 (1.6%) 22 (36.1%) 38 (62.3%) 
I would feel comfortable sharing 
my pronouns with my genetic 
counselor as soon as I am called 
from the waiting room. 
5 (8.2%) 9 (14.8%) 25 (41%) 22 (36.1%) 
I would feel comfortable sharing 
my pronouns with my genetic 
counselor when I am inside their 
office. 
1 (1.6%) 4 (6.6%) 30 (49.2%) 26 (42.6%) 
I would feel comfortable sharing 
my pronouns after the genetic 
counselor shared theirs. 
1 (1.6%) 3 (4.9%) 19 (31.2%) 37 (60.7%) 
I would feel comfortable 
disclosing any gender-affirming 
hormones and surgeries I've had 
on an intake form before my 
genetic counseling appointment. 
0 (0%) 11 (18%) 21 (34.4%) 28 (45.9%) 
I would feel comfortable 
disclosing any gender-affirming 
hormones and surgeries I've had 
during my genetic counseling 
appointment. 
0 (0%) 3 (4.9%) 26 (42.6%) 30 (49.2%) 
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Figure 2.4 Participant responses to questions regarding the importance of inclusivity 
before and during genetic counseling appointments and comfort with sharing cancer risk 
information with relatives. 
 
Although comfort levels between sharing pronouns, hormone history, and surgical 
history was not significantly different between being asked on an intake form or in 
person, respondents expressed the highest level of agreement to “I would feel 
comfortable sharing my pronouns on an intake form before my genetic counseling 
appointment” (p=0.65; Figure 2.5). Between available options for pedigree 
nomenclature, respondents were significantly less comfortable with being represented as 
their sex assigned at birth (H(2)=39.88, p=2.18E-09; Figure 2.6).  
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Figure 2.5 Participant responses to questions regarding the most comfortable way to 
disclose pronouns, hormone use, and surgical history.  
 
Figure 2.6 Participant responses to questions regarding comfort levels with current 
pedigree nomenclature.  
 
2.4.4 Motivations 
Roughly two-thirds of participants strongly agreed that they would value discussing 
hormone therapies and gender-affirming surgeries in relation to personal cancer risk 
during a genetic counseling session. Other motivations for which participants expressed a 
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high level of agreeance with included to gain information about personal cancer risk 
assistance as well as understanding options for cancer prevention, risk-reduction, and 
detection (Table 2.6; Figure 2.7; Figure 2.8). Although a majority of participants 
expressed agreement with the statements “I would value learning about the cancer risk 
for my relatives,” and “I would value discussing how my cancer risk could impact my 
family planning decisions,” these ranked the lowest among the agreed with statements 
(Figure 2.7).  
 












I would value learning about my 
personal cancer risk. 
0 (0%) 0 (0%) 30 (50%) 30 (50%) 
I would value learning about the 
cancer risk for my children. 
4 (6.9%) 9 (15.5%) 16 (27.6%) 16 (27.6%) 
I would value learning about the 
cancer risk for my relatives. 
1 (1.7%) 7 (11.9%) 32 (54.2%) 19 (32.2%) 
I would value having someone to 
help me understand how my 
personal and family history 
impacts my cancer risk. 
0 (0%) 1 (1.7%) 29 (49.2%) 29 (49.2%) 
I would value discussing my 
thoughts and feelings about my 
cancer risk. 
0 (0%) 3 (5.1%) 29 (49.2%) 26 (44.1%) 
I would value discussing my 
thoughts and feelings about my 
genetic test results. 
0 (0%) 1 (1.7%) 26 (44.1%) 31 (52.5%) 
I would value discussing my 
thoughts and feelings about 
cancer screening procedures. 
0 (0%) 2 (3.4%) 31 (52.5%) 26 (44.1%) 
I would value discussing how my 
cancer risk could impact my 
family planning decisions. 
2 (3.4%) 10 (17%) 20 (33.9%) 18 (30.5%) 
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I would value discussing 
hormone therapies and gender-
affirming surgeries as they relate 
to my cancer risk. 
1 (1.7%) 0 (0%) 20 (34.5%) 37 (63.8%) 
I would value having someone to 
help me understand my options 
for cancer detection. 
0 (0%) 2 (3.4%) 27 (45.8%) 30 (50.9%) 
I would value having someone to 
help me understand my options 
for cancer prevention and risk-
reduction. 
0 (0%) 0 (0%) 23 (39%) 36 (61%) 
I would value having someone to 
help me decide if genetic testing 
is right for me. 
0 (0%) 0 (0%) 27 (45.8%) 30 (50.9%) 
I would value discussing costs 
relating to genetic testing and 
follow-up screening. 
0 (0%) 1 (1.7%) 23 (39%) 35 (59.3%) 
I would value having someone to 
help me understand the privacy 
and confidentiality policies 
surrounding genetic test results. 
0 (0%) 3 (5.1%) 29 (49.2%) 26 (44.1%) 
Figure 2.7 Participant responses to questions regarding motivations related to personal 




Figure 2.8 Participant responses to questions regarding motivations related to genetic 
testing and cancer detection, prevention, and risk-reduction.  
 
Most respondents have taken or have considered taking gender-affirming hormones 
(Table 2.7). A majority of participants have had or have considered having chest or breast 
surgery. Almost half of participants who were born with ovaries have had or considered 
having an oophorectomy and over half of respondents who were born with a uterus have 
had or considered having a hysterectomy. Of the participants who were born with a 
prostate, most have not had or considered having a prostatectomy.  
 





Prefer not to say 
N (%) 
Have you ever taken, or considered 
taking, gender-affirming hormones? 
53 (88%) 7 (12%) 0 (0%) 
Have you ever had, or considered 
having, surgery on your breast tissue 
(lumpectomy, mastectomy, breast 
augmentation, chest reconstruction)? 
49 (82%) 8 (13%) 3 (5%) 
If you were born with ovaries, have 
you ever had, or considered having, 
19 (48%) 10 (25%) 11 (28%) 
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surgery to remove your ovaries 
(oophorectomy)? 
If you were born with a uterus, have 
you ever had, or considered having, 
surgery to remove your uterus 
(hysterectomy)? 
22 (54%) 10 (24%) 9 (22%) 
If you were born with a prostate, have 
you ever had, or considered having, 
surgery to remove your prostate 
(prostatectomy)? 
4 (21%) 14 (74%) 1 (5%) 
 
2.4.5 Qualitative Results 
In each survey, participants had the opportunity to answer open-text response 
questions and provide information or elaborate on the responses they provided. Of the ten 
individuals who were contacted, six participants completed a follow-up telephone 
interview. Direct quotes are extracted from open-text entries and telephone interview.  
When given the opportunity to expand on their family history of cancer, some 
individuals specified which relatives had cancer, provided information about “other” 
types of cancer, and/or explained why they did not know about their family history of 
cancer. The amount of detail provided by each participant varied greatly and did not 
correlate with the amount of information the participant indicated they knew about their 
family medical history. Listed below are quotes from participants regarding their family 
history of cancer. 
1. “Dad died of prostate cancer. Brother had a prostatectomy.” 
2. “Great-grandmother had breast cancer.” 
3. “Grandmother had colon cancer in her early 50s. At 73 she developed stomach, 
liver, and other cancer that had metastasized from which she passed of within 2 
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weeks of diagnosis. Prostate cancer from maternal grandfather’s brother. 
Bladder cancer from maternal uncle.” 
4. “Maternal grandmother and sister both died from ovarian and endometrial 
cancer.” 
5. “The ‘other’ cancers are basal cell carcinomas.” 
6. “My aunt had breast cancer and received chemo and they removed her breast 
tissue on that side. Another aunt had [ovarian] cancer.” 
7. “2 aunts of mother’s side, my father, 1+ on my father’s side. Family is fractured, 
data incomplete.” 
8. “I don’t know because I’m adopted with no contact with [my biological] family. I 
was diagnosed with a ductal hyperplasia” 
Listed below are quotes from participants regarding comfort levels with current 
genetic counseling pedigree nomenclature and suggestions for fostering inclusivity as a 
healthcare professional. 
9. “I understand in the medical field it can be important to look at birth gender 
when assessing risks or looking at treatments, so it wouldn't bother me to have 
that information be a part of the process. I would just prefer being referred to as 
my chosen gender and pronouns when we're speaking and on any regular 
paperwork.” 
10. “I usually don’t mind sharing any hormone related medication on intake forms, 
surgeries are usually left unstated unless such information is deemed necessary.” 
11. “I would only be comfortable with the AFAB identifier after gender affirming 
surgery.” 
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12. “We live our lives mostly telling people who we are. It's much nicer to write it 
down and pass it to said people of an office rather than someone saying out loud 
in front of strangers. Also, being asked is so much nicer and more comfortable 
than having to correct someone or tell them straight forward what you prefer.” 
13. “Having a pronoun field on the intake sheet helps to standardize sharing 
pronouns and is a great step to making the process more inclusive.” 
14. “I've been very fortunate in my medical experiences so far, but I'm always a little 
nervous when seeing a new doctor for the first time. Seeing some sort of LGBT+ 
support information in the lobby or on their website would be very comforting.” 
15. “Medical facilities should always be safe places because you are poked and 
tested so much anyways. It is important to still keep up with doctors to know the 
health of your body and you should never feel scared to go to the doctors you 
need [because you are transgender]. [Healthcare is] needed to sustain a long and 
healthy life. So, it should be apparent from the moment you touch the front door 
of an office with a sticker or sign saying, “we include everyone including 
LGBTQ+”. Some of the worst moments of my life have been in a doctor’s office 
and I don’t want that for others.” 
Listed below are quotes from participants regarding potential motivations for seeking 
cancer genetic counseling. Some participants expanded on what they would like to have 
addressed during a session and other provided insight on why certain statements were 
less motivating.    
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16. “We always hear that there are risks from taking [hormones] but there is never a 
long conversation about exactly what those risks are, especially about cancer, 
nobody really asks about that.” 
17. “Given our understanding of how transgender hormone therapies and surgeries 
are still not well understood in the long term, I would find it very helpful to have 
some of that information included in an overview of my potential cancer risks.” 
18. “I have always planned to foster/adopt children and do not plan on having any 
biological children.”  
19. “It would be nice to have someone say, ‘this is your risk and here’s why,’ so if a 
genetic counselor could do that, I would go.” 
20. “I feel like I would just want to make sure I was doing the right cancer 
screenings, so I don’t get blindsided by anything.” 
2.5 Discussion 
2.5.1 Discussion 
This study explored perspectives of transgender individuals who may present for 
hereditary cancer genetic counseling regarding the primary informational and 
psychosocial needs, motivations for seeking cancer counseling, and barriers to accessing 
or attending genetic counseling. The purpose of this study was to gain a better 
understanding of what areas of current genetic counseling practice and formal education 
need to be evolved to provide optimized, comprehensive, and inclusive care for this 
patient population. While the perceptions of genetic counselors on trans-inclusive 
counseling have been investigated previously (Barnes et al., 2019; Berro et al., 2019; 
Sacca et al., 2019; Sheehan et al., 2020; Zayhowski, et al., 2019) each of these studies 
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calls for a direct assessment of patient-reported educational and psychosocial needs of 
transgender patients. 
We predicted that transgender and nonbinary individuals would have needs within the 
cancer genetic counseling session that are similar to cisgender patients, as well as needs 
that are unique to their gender identity. We expected that participants would find value in 
and be motivated by the opportunity to discuss how future healthcare plans regarding 
hormone and surgical transitioning could be impacted by a hereditary predisposition to 
cancer. We also aimed to obtain clarification on opinions on the current, official pedigree 
nomenclature standards. 
The information revealed in this study is similar to what has been previously reported 
for transgender patients in genetic counseling in general, emphasizing the importance of 
adapting to the self-reported needs of this patient population. Specific themes highlighted 
are that transgender individuals have both similar and diverse motivations and needs 
related to hereditary cancer genetic counseling, patient agreeance with the current and 
proposed pedigree nomenclature varies between methodologies, and that there are 
barriers to accessing care that genetic counselors should be aware of and take into 
consideration while counseling transgender patients. 
Common motivations among both transgender and cisgender individuals regarding 
seeking hereditary cancer genetic counseling include learning about personal cancer risk, 
attempting to better understand options for cancer prevention and risk-reduction, and 
having someone to help that individual decide if, and when, genetic testing may be right 
for them. Since every respondent either agreed or strongly agreed with those statements, 
it can be inferred that these motivations are not impacted by gender identity and would be 
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the same across both cisgender and transgender patient populations. All respondents 
agreed with the statement about cancer prevention and risk-reduction was unexpected 
because transgender patients typically have an extremely low uptake and adherence to 
most cancer screening recommendations compared to cisgender patients of the same age 
and health status (Bazzi et al., 2015; Tabaac et al. 2018). Patients who are currently 
employed, have higher annual incomes, have completed higher levels of education, and 
have health insurance are more likely to adhere to cancer screening and prevention 
recommendations than those who do not (Johnson et al., 2016). A potential explanation 
for the strong agreeance with learning about cancer prevention and risk-reduction could 
be the unequal distribution of participants who are employed and have private health 
insurance. We found that these participants are more likely to receive medical care from a 
center that specializes in transgender healthcare, which could increase comfort and access 
to cancer screenings that transgender patients may not otherwise seek.  
Roughly half of participants said they would be motivated to learn about the cancer 
risk for their children and other relatives. For most cisgender cancer genetic counseling 
patients, genetic counselors discuss familial implications and how these family members 
could be impacted by the patient pursuing genetic testing, in terms of both benefits and 
limitations. Although many participants indicated agreeance with learning this 
information, the concordance was not as high as that seen for other topics. This may 
result in less time needing to be spent on this topic in a cancer genetic counseling session. 
Unsurprisingly, all but one participant agreed or strongly agreed that discussing hormone 
therapies and gender-affirming surgeries as they relate to personal cancer risk would be a 
motivating factor for seeking genetic counseling, which is a need specific to this patient 
44 
population. Most respondents reported that they have or have considered both surgical 
and hormonal therapies as a part of their transition process. Participants cited the lack of 
concrete information regarding cancer risks associated with hormone use as one reason 
that they would like to discuss hormone use during a genetic counseling session. There 
are some cisgender patients who may have had previous chest or breast surgery, an 
oophorectomy, a hysterectomy, or taken hormones, however the frequency of these 
surgical interventions and hormonal therapies in the cisgender population is significantly 
less than in the transgender population. In addition, depending on age at time of 
evaluation, transgender patients may have a longer history of hormone use.  
Participants were asked to indicate their level of agreement with the comfortability, 
and therefore appropriateness, of current guidelines and proposed changes to pedigree 
nomenclature regarding gender. Most participants disagreed or strongly disagreed with 
being represented as their sex assigned at birth on a pedigree, which is one interpretation 
of the latest NSGC guidelines which indicate that it is appropriate to assign gender based 
on phenotype. This information supports previous data that calls for revision and 
standardization of pedigree nomenclature to increase comfort of patients while 
maintaining accuracy (Barnes et al., 2019; Rafferty 2018; Sheehan et al., 2020). 
Participants were most comfortable being represented as their gender identity with an 
abbreviation of their sex assigned at birth under the symbol. Genetic counselors and 
transgender individuals alike have proposed an additional symbol, a hexagon, that would 
indicate a nonbinary individual rather than not specifying their gender (Sheehan et al., 
2020; von Vaupel-Klein, & Walsh, 2020). The data from this study supports that 
proposal, as most participants would feel most comfortable being represented as their 
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gender identity, and there are currently no symbols outside of the binary male and female, 
or unknown gender. It is inappropriate to indicate that a transgender or nonbinary patient 
is an unknown gender if they identify with either, or both, of those genders.  
2.5.2 Practice Implications 
Patients expressed that it would be more comfortable to share pronouns and hormonal 
and surgical interventions on an intake form prior to the genetic counseling appointment, 
as opposed to in person during the visit. Some individuals expressed that having an 
inclusive intake form is a way to build trust between the healthcare provider and the 
patient before they meet. Genetic counselors seeing patients for hereditary cancer 
evaluations, as well as in other settings, should make a conscious effort to revise their 
current intake procedures to include the option for “other” genders besides the binary 
male and female in addition to asking about pronouns, which may go along with 
“preferred name” or “title” sections that are already a part of many institution’s intake 
paperwork. Increased comfort with providers builds trust between that provider and the 
patient, which may ultimately lead to stronger adherence to recommendations, such as a 
cancer screening.  
Creation and implementation of a standardized pedigree nomenclature that includes 
appropriate designations for transgender and nonbinary individuals is a crucial next step 
for the profession. A revision of the current NSGC Standardized Pedigree Nomenclature 
will allow this patient population to be represented accurately while setting the example 
for other professional societies to make adjustments to their pedigree nomenclature that 
supports inclusive patient care.  
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Since most patients were motivated by the desire to discuss how their hormone and 
surgical history impacts their cancer risk, it is important for genetic counselors to be 
aware of which hormone therapies and surgical approaches are commonly available to 
transgender patients and how these may be similar or different to hormone therapies and 
surgeries that may be recommended or included in cancer management of cisgender 
patients. For example, it would be important for cancer genetic counselors to know 
gender-affirming masculinizing top surgeries do not reduce breast cancer risk 
equivalently to a risk-reducing bilateral mastectomy, which is recommended in some 
cases of hereditary cancer. It has been shown that healthcare providers with professional 
education and formal training regarding care for lesbian, gay, bisexual, transgender, and 
questioning individuals demonstrate an increase in knowledge and competency when 
serving these patient populations (Hardacker et al. 2014; Johnson et al. 2016). Therefore, 
genetic counselors would benefit from formal education either during their training 
programs or as a part of continuing education.  
2.5.3 Limitations and Future Research 
The results of this study are limited by a small sample size (n=87), which inhibited 
the ability to assess significance of data. Sample size may be partially explained by the 
requirement that participants be fluent in English reading and writing. In addition, our 
demographics were heavily skewed towards college-educated, Caucasian participants, 
therefore these findings may not be generalized to ethnic minority transgender 
individuals or transgender individuals who have not entered any post-secondary 
education. The utility of investigation of the same themes in transgender people of racial 
and ethnic minorities as well as diverse education levels lies in comparing the data from 
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this study and similar studies to data gathered from a population where additional 
intersectional health equities are present.  
In order to be eligible for participation in this study, participants had to be 18 years of 
age or older. Our study was primarily composed of respondents between the ages of 18- 
and 38-years-old. Identified themes from this study may not be representative of other 
cohorts. It may be beneficial in future research studies to explore the perspectives of 
transgender individuals who are under the age of 18, as it is more likely that minors have 
not yet begun hormonal or surgical therapies, which may have an effect on motivations 
and needs in a cancer genetic counseling setting. This information could inform when 
transgender patients should be asked about family history of cancer and henceforth 
referred to genetic counseling when appropriate. Providing early cancer risk education 




Transgender individuals have both similar and diverse motivations and needs related 
to hereditary cancer genetic counseling when compared to cisgender individuals. 
Common motivations among both patient populations include learning about personal 
cancer risk, attempting to better understand options for cancer prevention and risk-
reduction, and having someone facilitating the decision-making process surrounding 
hereditary cancer genetic testing. 
Implications regarding children and other relatives was not found to be strongly 
motivating, although these are common motivations in cisgender patients. Transgender 
patients have unique needs in terms of risk education regarding hormone use and surgical 
interventions. Many transgender individuals will have or will consider both hormonal and 
surgical interventions, which may or may not impact cancer risk. Genetic counselors 
should be prepared to address this topic during sessions with transgender patients, which 
would be best supported by formal education on transgender healthcare needs.  
Transgender patients may be more comfortable disclosing information regarding 
pronouns and hormonal and surgical history on an intake form, rather than in person with 
the genetic counselor. It is important that genetic counselors take this into consideration 
when creating and revising intake forms. Allowing patients to indicate a gender other 
than male or female, or list their pronouns, is one way to be inclusive and foster a 
comfortable setting for transgender patients. Another effort towards inclusivity would be 
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the creation and implementation of a standardized pedigree nomenclature that includes 
appropriate designations for transgender and nonbinary individuals, taking their 
suggestions and preferences into consideration.
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PARTICIPANT RECRUITMENT SOCIAL MEDIA TEXT 
The following text was posted to various social media platforms with a direct link to the 
survey.  
 
Jacqueline Baquet, a genetic counseling student at the University of South Carolina, is 
working on a thesis project to assess the needs of transgender individuals in a cancer 
genetic counseling setting. This is an online survey for individuals whose gender identity 
does not align with their gender assigned at birth. 
Please consider participating if any of the following applies to you: 
• Have or have had cancer yourself 
• Have relatives that have or have had cancer 
• Are interested in learning about your cancer risks 
• Are interested in learning about genetic testing for hereditary cancer 
• Are interested in contributing to research that will benefit this healthcare field 
Please share this post with anyone who may be eligible to participate in this survey. 
Upon completion of the survey, you will be offered the option to enter a raffle for one of 






The following list of questions was used as an outline for the questionnaire after inclusion 
criteria was met.  
Where appropriate, the interviewees were asked to expand upon their answers. 
1. Please select the gender(s) that best describe you: 
2. Have you ever been diagnosed with cancer? 
i. What type of cancer(s) have you been diagnosed with?  
ii. How old were you when you were diagnosed with cancer? 
3. How much do you feel you know about your family medical history? 
4. Please select the number of relatives that have been diagnosed with the following 
cancers: 
 i. Breast cancer 
 ii. Ovarian cancer 
 iii. Gastric/stomach cancer 
 iv. Colon/rectal cancer 
 v. Pancreatic cancer 
 vi. Melanoma 
 vii. Prostate cancer 
 viii. Endometrial/uterine cancer 
 ix. Other cancer 
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 x. Unsure what type of cancer  
4. Please select a response to the following considerations regarding a cancer genetic 
counseling appointment: 
i. If I was at an increased risk to develop cancer due to a genetic cause, I would 
feel comfortable sharing this with my relatives without assistance from a genetic 
counselor. 
ii. If I was at an increased risk to develop cancer due to a genetic cause, I would 
feel comfortable sharing this with my relatives with assistance from a genetic 
counselor like a family letter, phone call, or follow-up appointment. 
iii. It is important to me that medical intake forms ask about gender identity in an 
inclusive way. 
iv. It is important to me that medical professionals exchange pronouns with me. 
v. It is important to me that medical professionals use inclusive language during 
an appointment. 
vi. It is important to me that I am represented in my medical records as my 
gender, rather than my gender assigned at birth. 
vii. It is important to me that medical offices display signs or other visual 
representations of LGBTQ+ inclusivity in their waiting room. 
5. Please select a response to the following considerations regarding a cancer genetic 
counseling appointment: 




ii. I would feel comfortable sharing my pronouns on an intake form before my 
genetic counseling appointment. 
iii. I would feel comfortable sharing my pronouns with my genetic counselor as 
soon as I am called from the waiting room. 
iv. I would feel comfortable sharing my pronouns with my genetic counselor 
when I am inside their office. 
v. I would feel comfortable sharing my pronouns after the genetic counselor 
shared theirs. 
vi. I would feel comfortable disclosing any gender-affirming hormones and 
surgeries I've had on an intake form before my genetic counseling appointment. 
vii. I would feel comfortable disclosing any gender-affirming hormones and 
surgeries I've had during my genetic counseling appointment. 
viii. I would feel comfortable being represented on the official pedigree as my 
gender identity with AFAB/AMAB written underneath. 
ix. I would feel comfortable being represented on the official pedigree as some 
combination of my assigned sex and gender identity. 
x. I would feel comfortable being represented on the official pedigree as my sex 
assigned at birth. 
6. Please select a response to the following considerations regarding a cancer genetic 
counseling appointment: 
 i. I would value learning about my personal cancer risk. 
 ii. I would value learning about the cancer risk for my children. 
 iii. I would value learning about the cancer risk for my relatives. 
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iv. I would value having someone to help me understand how my personal and 
family history impacts my cancer risk. 
v. I would value discussing my thoughts and feelings about my cancer risk. 
vi. I would value discussing my thoughts and feelings about my genetic test 
results. 
vii. I would value discussing my thoughts and feelings about cancer screening 
procedures. 
viii. I would value discussing how my cancer risk could impact my family 
planning decisions. 
ix. I would value discussing hormone therapies and gender-affirming surgeries as 
they relate to my cancer risk. 
x. I would value having someone to help me understand my options for cancer 
detection. 
xi. I would value having someone to help me understand my options for cancer 
prevention and risk-reduction. 
xii. I would value having someone to help me decide if genetic testing is right for 
me. 
xiii. I would value discussing costs relating to genetic testing and follow-up 
screening. 
xiv. I would value having someone to help me understand the privacy and 
confidentiality policies surrounding genetic test results. 
7. Have you ever taken, or considered taking, gender-affirming hormones? 
8. Have you ever had, or considered having, surgery on your breast tissue? 
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9. Were you born with ovaries? 
 i. Have you ever had, or considered having, surgery to remove your ovaries? 
10. Were you born with a uterus? 
 i. Have you ever had, or considered having, surgery to remove your uterus? 
11. Were you born with a prostate? 
 i. Have you ever had, or considered having, surgery to remove your prostate? 
12. What is your age? 
13. Please select the race(s) that best describe you: 
14. Please select the ethnicity that best describes you: 
15. Please select the highest level of education you have completed: 
16. Please select your employment status: 
17. Please select the annual income that best describes your household: 
18. Please select your current health insurance:  







The following list of questions was used as an outline for the phone interview questions. 
1. What are your pronouns? 
2. How do you feel about discussing cancer risks with your family?  
3. What about with your doctors?  
4. Which of your doctors have asked you about your cancer family history? 
i. What did they say? 
ii. Is this something you wish would have been addressed? 
5. Has any doctor ever talked to you about cancer as it relates to any hormones you have 
taken or surgeries you have had? 
i. What did they say? 
ii. Is this something you wish would have been addressed? 
6. Can you tell me about what you have been told regarding cancer screening? 
7. How do you feel about cancer screenings? 
 i. Have you had any cancer screenings yourself? What type? Why not?  
8. Do you think you might feel differently if you knew you were at an increased risk for 
developing cancer?  
9. What makes you most comfortable when visiting a new healthcare office? 
10. What do you see as the largest benefit of pursuing cancer genetic counseling? What 
would be your largest reservation about pursuing cancer genetic counseling? 
